Search results
Results from the WOW.Com Content Network
The WHO-prequalified vaccine, called TAK-003, is recommended for children 6–16 years old who are in environments where dengue spread is high and burdensome on public health.
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
Takeda's vaccine, given in two doses over a three-month interval, protects against four serotypes of the dengue virus. It was cleared by WHO for use in children aged 6 to 16 in areas with high ...
RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's ...
It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy, [6] [7] and only the second malaria vaccine to be recommended by the WHO. [8] In April 2023, Ghana's Food and Drugs Authority approved the use of the R21 vaccine for use in children aged between five months and three ...
A new vaccine candidate was more than 83 percent effective at protecting against hospitalizations over a three-year clinical trial. Dengue virus is a mosquito-borne disease that can cause severe ...
Two types of dengue vaccine have been approved and are commercially available. Dengvaxia became available in 2016, but it is only recommended to prevent re-infection in individuals who have been previously infected. [13] The second vaccine, Qdenga, became available in 2022 and is suitable for adults, adolescents and children from four years of ...
President Benigno Aquino III at the launching of the dengue vaccine school-based immunization program. In April 2016, the DOH launched the dengue vaccination campaign in Central Luzon, Calabarzon and Metro Manila, where about 700,000 individuals received at least one dose of the vaccine. [11] The government paid P3.5-billion for the vaccine. [10]